VX-973 / Vertex - LARVOL DELTA

VX24-973-002: A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed

Trial completion • Pain

VX24-973-002: A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P1 trial • Pain

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Apr 2024 | Trial primary completion date: Nov 2024 ➔ Apr 2024

Trial completion • Trial completion date • Trial primary completion date • Pain

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting | N=80 ➔ 30

Enrollment change • Enrollment closed • Pain

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial completion date: Apr 2024 ➔ Nov 2024 | Trial primary completion date: Apr 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Pain

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P1 trial • Pain